DexCom earnings beat by $0.03, revenue topped estimates
Techne Corp (NASDAQ:TECH)’s stock has experienced a notable downturn, touching a 52-week low of $61.16. According to InvestingPro data, the company currently trades at a relatively high P/E ratio of 61.5, with analyst price targets ranging from $68 to $95, suggesting potential upside despite recent weakness. This latest price level reflects a significant retreat from previous valuations, marking a challenging period for the company amidst a dynamic market environment. Over the past year, Techne Corp has seen its stock value decrease by 12%, with a year-to-date decline of 10.83%. Despite the bearish sentiment, InvestingPro analysis reveals strong fundamentals, including sufficient cash flows to cover interest payments and healthy liquidity ratios. Discover 10+ additional exclusive insights and a comprehensive Pro Research Report available on InvestingPro. This downturn presents a critical moment for Techne Corp, a $9.69 billion market cap company, as it navigates through market pressures and strives to regain its footing in the competitive landscape.
In other recent news, Bio-Techne Corporation reported its Q4 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.42, beating the forecast of $0.39. The company also reported revenue of $297 million, exceeding the anticipated $286.14 million, marking a 4% year-over-year increase. This strong financial performance was further highlighted by a 5% growth in net gross profit, reaching $95 million, and a significant rise in EBITDA to $21.3 million. In addition to financial achievements, Bio-Techne launched a Good Manufacturing Practice (GMP) grade transposase mRNA for its TcBuster genome engineering system, aimed at advancing cell therapy development. This new product is designed to facilitate gene editing in immune and stem cell therapies without using viral vectors, potentially reducing time to market and lowering costs for developers. The company emphasized the advantages of the TcBuster system over traditional methods, such as a reduced insertional risk profile and the elimination of viral clearance needs. Bio-Techne’s strategic initiatives, including product launches and partnerships, continue to contribute to its growth trajectory. The company reported approximately $1.2 billion in net sales for fiscal 2024, indicating robust business operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.